1 OMS. Stratégie mondiale du secteur de la santé contre l’hépatite virale 2016–2021. Genève: Organisation mondiale de la santé, 2016.
2 Bobzin C, Bösiger C, Bruggmann P, Cerny A, Fraga Christinet M, Keiser O, et al. Recommandations pour le suivi des patients atteints d’hépatite C guérie. Forum Med Suisse. 2021;21(11–12): 184–6.
3 Schmid P, Bregenzer A, Huber M, Rauch A, Jochum W, Müllhaupt B, et al. Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy. PloS one. 2015;10(9):e0138838.
4 European Association for the Study of the Liver. EASL-recommendations on treatment of hepatitis C. J Hepatol. 2020;73(5):1170–218.
5 Hajarizadeh B, Cunningham EB, Valerio H, Martinello M, Law M, Janjua NZ, et al. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. J Hepatol. 2019;72(4):643–57.
6 Ioannou GN, Feld JJ. What are the benefits of a sustained virologic response to direct-acting antiviral therapy for hepatitis C virus infection? Gastroenterology. 2019;156:446–60.e2.
7 Surial B, Bertholet N, Daeppen JB, Darling KEA, Calmy A, Günthard HF, et al., The Swiss Hiv Cohort Study. The Impact of Binge Drinking on Mortality and Liver Disease in the Swiss HIV Cohort Study. J Clin Med. 2021;10(2):295.
8 Prasad L, Masserey Spicher V, Zwahlen M, Rickenbach M, Helbling B, Negro F, Swiss Hepatitis C Cohort Study Group. Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS). Int J Epidemiol. 2007;36(4):731–7.